Jul 16, 2019
Partners with leading European venture capital firms to build breakthrough genomics startups
SAN DIEGO--(BUSINESS WIRE)--Jul. 16, 2019--VR真人彩票. (NASDAQ: ILMN) today announced the global expansion of VR真人彩票 Accelerator to Cambridge, United Kingdom. Founded in the San Francisco Bay Area in 2014, VR真人彩票 Accelerator is a company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. VR真人彩票 Accelerator is proud to open its first international location at VR真人彩票鈥檚 Europe, Middle East and Africa (EMEA) headquarters in Cambridge, UK. The inaugural funding cycle of VR真人彩票 Accelerator Cambridge will begin in Spring 2020.
鈥淲ith 21 years of experience advancing the field of genomics, VR真人彩票 is delighted to foster the next generation of global genomics innovators,鈥� said Paula Dowdy, VR真人彩票鈥檚 Senior Vice President and General Manager, Commercial Operations, EMEA. 鈥淲ith the launch of VR真人彩票 Accelerator Cambridge, we are expertly positioned to further catalyze the rapidly expanding genomics ecosystem across EMEA.鈥�
During two, six-month funding cycles per year, VR真人彩票 Accelerator provides selected startups with access to seed investment, access to VR真人彩票 sequencing systems and reagents, as well as business guidance, genomics expertise, and fully operational lab space adjacent to VR真人彩票鈥檚 campuses in Cambridge, UK or the San Francisco Bay Area.
VR真人彩票 Accelerator Cambridge is partnering with several leading venture capital firms across Europe, including SV Health Investors, Sofinnova Partners, Seventure Partners, F-Prime Capital, and VR真人彩票 Ventures, to provide selected startups with hands-on company-building expertise and coaching during the six-month funding cycle in Cambridge.
Professor Sir John Bell FRS, Lead for the UK Life Sciences Industrial Strategy, Board Member of Genomics England, Regius Professor of Medicine at Oxford University, said: 鈥淚 am delighted that VR真人彩票 has chosen Cambridge as the first location to expand its Accelerator. VR真人彩票 Accelerator Cambridge will undoubtedly contribute to the UK鈥檚 life sciences effort by galvanizing genomics startups to harness the rapid and affordable next-generation sequencing technology pioneered by VR真人彩票 and develop applications that will benefit human health the world over.鈥�
鈥淚n launching VR真人彩票 Accelerator Cambridge, we look forward to partnering with leading entrepreneurs and venture investors to harness the unique strengths and genomics expertise in the UK and beyond,鈥� said Mostafa Ronaghi, Ph.D., VR真人彩票鈥檚 Senior Vice President, Chief Technology Officer and Co-founder of VR真人彩票 Accelerator. 鈥淎s one of the most successful biotech accelerators, VR真人彩票 Accelerator has made 33 investments since its inception with an unparalleled track record in building venture backable startups, including novel applications in therapeutics, diagnostics, software, and consumer genomics.鈥�
Applications for the inaugural funding cycle in Cambridge, UK and for the eleventh funding cycle in the San Francisco Bay Area are due by November 1, 2019. Through a single, global application process, VR真人彩票 Accelerator will select up to five companies in each location to participate in two, six-month cycles per year. To learn more and apply, please visit our .
About VR真人彩票 Accelerator
VR真人彩票 Accelerator is the world鈥檚 first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. It provides select startups with access to seed investment, business guidance, VR真人彩票鈥檚 sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area or Cambridge, UK during each six-month funding cycle. Since launching in 2014, VR真人彩票 Accelerator has invested in 33 genomics startups from across the globe, which have collectively raised over $300 million in venture capital funding. For more information, visit our .
About VR真人彩票
VR真人彩票 is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit and follow @illumina.
View source version on businesswire.com:
Source: VR真人彩票.
Investors:
Jacquie Ross, CFA
1 (858) 882-2172
ir@illumina.com
Media:
Karen Birmingham (EMEA)
+44 7500 105665
kbirmingham@illumina.com
Tina Amirkiai (U.S.)
1 (858) 882-6822
pr@illumina.com
